A global action agenda for turning the tide on fatty liver disease
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND AND AIMS: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care.
APPROACH AND RESULTS: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of "agree" responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% "agree"). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance.
CONCLUSIONS: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 79(2024), 2 vom: 01. Feb., Seite 502-523 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/HEP.0000000000000545 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360398790 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360398790 | ||
| 003 | DE-627 | ||
| 005 | 20240313233543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HEP.0000000000000545 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM360398790 | ||
| 035 | |a (NLM)37540183 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lazarus, Jeffrey V |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A global action agenda for turning the tide on fatty liver disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND AND AIMS: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care | ||
| 520 | |a APPROACH AND RESULTS: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of "agree" responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% "agree"). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance | ||
| 520 | |a CONCLUSIONS: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Mark, Henry E |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Alina M |e verfasserin |4 aut | |
| 700 | 1 | |a Arab, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Carrieri, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Noureddin, Mazen |e verfasserin |4 aut | |
| 700 | 1 | |a Alazawi, William |e verfasserin |4 aut | |
| 700 | 1 | |a Alkhouri, Naim |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Saleh A |e verfasserin |4 aut | |
| 700 | 1 | |a Anstee, Quentin M |e verfasserin |4 aut | |
| 700 | 1 | |a Arrese, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bataller, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Berg, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Brennan, Paul N |e verfasserin |4 aut | |
| 700 | 1 | |a Burra, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Castro-Narro, Graciela E |e verfasserin |4 aut | |
| 700 | 1 | |a Cortez-Pinto, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Cusi, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Dedes, Nikos |e verfasserin |4 aut | |
| 700 | 1 | |a Duseja, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Francque, Sven M |e verfasserin |4 aut | |
| 700 | 1 | |a Gastaldelli, Amalia |e verfasserin |4 aut | |
| 700 | 1 | |a Hagström, Hannes |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Terry T K |e verfasserin |4 aut | |
| 700 | 1 | |a Ivancovsky Wajcman, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Kautz, Achim |e verfasserin |4 aut | |
| 700 | 1 | |a Kopka, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Krag, Aleksander |e verfasserin |4 aut | |
| 700 | 1 | |a Newsome, Philip N |e verfasserin |4 aut | |
| 700 | 1 | |a Rinella, Mary E |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Sarin, Shiv Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Spearman, C Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Terrault, Norah A |e verfasserin |4 aut | |
| 700 | 1 | |a Tsochatzis, Emmanuel A |e verfasserin |4 aut | |
| 700 | 1 | |a Valenti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Villota-Rivas, Marcela |e verfasserin |4 aut | |
| 700 | 1 | |a Zelber-Sagi, Shira |e verfasserin |4 aut | |
| 700 | 1 | |a Schattenberg, Jörn M |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Vincent Wai-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Younossi, Zobair M |e verfasserin |4 aut | |
| 700 | 0 | |a on behalf of the Healthy Livers, Healthy Lives Collaborators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 79(2024), 2 vom: 01. Feb., Seite 502-523 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:502-523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HEP.0000000000000545 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 2 |b 01 |c 02 |h 502-523 | ||